ArticleCardiology and therapy2025
Treatment Patterns and Healthcare Resource Utilization Among Patients with Obstructive Hypertrophic Cardiomyopathy in Japan: A Claims Database Study.
Article in Cardiology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObstructive hypertrophic cardiomyopathy (HCM) increases the risk of developing cardiac complications and can impact long-term outcomes, necessitating appropriate treatment. However, real-world data on how patients with obstructive HCM are currently managed, especially in Japan, remain limited. This study evaluated pharmacological treatment patterns, incidence of nonpharmacological interventions, and healthcare resource utilization (HCRU) associated with obstructive HCM management in Japan.
methodsThis retrospective longitudinal study analyzed claims data (N = 12,503,399) provided by insurers between April 1, 2014, and December 31, 2022. The primary objective was to describe the treatment pattern of patients with obstructive HCM. Any medication changes (beta-blockers [BBs], non-dihydropyridine [DHP] calcium channel blockers [CCBs], and sodium channel blockers [SCBs]), incidence of nonpharmacological interventions, and HCRU were assessed.
resultsAmong 403 eligible patients, 72.5% were female, with a mean ± standard deviation age of 75.5 ± 11.7 years. The most common index medication was BB only (74.19%), followed by BB + SCB (10.42%), SCB (8.93%), BB + CCB (1.99%), CCB (3.72%), BB + CCB + SCB (0.5%), and CCB + SCB (0.25%). Overall, 123 (30.5%) patients experienced a treatment change within 12 months after the first prescription, of whom 5 (1.2%) switched to a different medication, 51 (12.7%) had an add-on to the index medication, and 67 (16.6%) discontinued their treatment. SCB was prescribed as initial treatment to 20.1% of patients. The discontinuation rate at 12 months was the highest for SCB (22%), followed by BB (16%) and CCB (12%). Dose reduction was the highest for SCB (22.2%), followed by BB (12%) and CCB (4%). The rate of nonpharmacological interventions (events/100 person-years) was similar for pacemaker implantation and septal ablation (2.0), followed by implantable cardioverter-defibrillators (1.2) and mitral valve replacement (1.1).
conclusionsThese findings will guide future research aimed at optimizing obstructive HCM management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.